Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hypertension and migraine comorbidity: prevalence and risk of cerebrovascular events: evidence from a large, multicenter, cross-sectional survey in Italy (MIRACLES study).
Mancia G, Rosei EA, Ambrosioni E, Avino F, Carolei A, Daccò M, Di Giacomo G, Ferri C, Grazioli I, Melzi G, Nappi G, Pinessi L, Sandrini G, Trimarco B, Zanchin G; MIRACLES Study Group. Mancia G, et al. J Hypertens. 2011 Feb;29(2):309-18. doi: 10.1097/HJH.0b013e3283410404. J Hypertens. 2011. PMID: 21119534
Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters.
Mantovani G, Madeddu C, Gramignano G, Lusso MR, Mocci M, Massa E, Ferreli L, Astara G, Macciò A, Serpe R. Mantovani G, et al. Among authors: mocci m. J Exp Ther Oncol. 2003 Jul-Aug;3(4):205-19. doi: 10.1046/j.1359-4117.2003.01096.x. J Exp Ther Oncol. 2003. PMID: 14567291 Clinical Trial.
Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress.
Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso MR, Massa E, Mocci M, Serpe R. Mantovani G, et al. Among authors: mocci m. J Mol Med (Berl). 2003 Oct;81(10):664-73. doi: 10.1007/s00109-003-0476-1. Epub 2003 Aug 19. J Mol Med (Berl). 2003. PMID: 12928788
Six-week induction chemotherapy followed by concomitant chemoradiation therapy in stage IV head and neck cancer: a phase II study with organ-sparing purposes.
Mantovani G, Massa E, Astara G, Murgia V, Gramignano G, Ferreli L, Camboni P, Lusso MR, Mocci M, Madeddu C, Mura L, Mudu MC, Proto E, Tore G, Mura M, Macciò A, Ferreli A, Amichetti M. Mantovani G, et al. Among authors: mocci m. Oncol Rep. 2003 May-Jun;10(3):759-66. Oncol Rep. 2003. PMID: 12684655 Clinical Trial.
The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression.
Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso MR, Murgia V, Camboni P, Ferreli L, Mocci M, Massa E. Mantovani G, et al. Among authors: mocci m. Free Radic Res. 2003 Feb;37(2):213-23. doi: 10.1080/10715760303849. Free Radic Res. 2003. PMID: 12653210
Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs.
Mantovani G, Massa E, Astara G, Murgia V, Gramignano G, Lusso MR, Camboni P, Ferreli L, Mocci M, Perboni S, Mura L, Madeddu C, Macciò A. Mantovani G, et al. Among authors: mocci m. Oncol Rep. 2003 Jan-Feb;10(1):197-206. Oncol Rep. 2003. PMID: 12469169 Clinical Trial.
Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy.
Mantovani G, Macciò A, Madeddu C, Mulas C, Massa E, Astara G, Ferreli L, Mudu MC, Gramignano G, Murgia V, Lusso MR, Mocci M, Cardia A, Mura L. Mantovani G, et al. Among authors: mocci m. Oncol Rep. 2002 Jul-Aug;9(4):887-96. Oncol Rep. 2002. PMID: 12066227 Clinical Trial.
12 results